IgA Nephropathy – Current and Future Perspectives in Treatment

1. Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol 2018; 38:435–42 SchenaFP NistorI Epidemiology of IgA nephropathy: a global perspective Semin Nephrol 2018 38 435 42 Search in Google Scholar

2. Cheung CHK, Barratt J. IgA nephropathy: Clinical features and diagnosis. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA. 2023 CheungCHK BarrattJ IgA nephropathy: Clinical features and diagnosis In: UpToDate PostTW (Ed), UpToDate Waltham, MA 2023 Search in Google Scholar

3. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011; 26:414–30 McGroganA FranssenCF de VriesCS The incidence of primary glomerulonephritis worldwide: a systematic review of the literature Nephrol Dial Transplant 2011 26 414 30 Search in Google Scholar

4. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368:2402–14. WyattRJ JulianBA IgA nephropathy N Engl J Med 2013 368 2402 14 Search in Google Scholar

5. Suzuki H, Kiryluk K, Novak J et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011; 22:1795–803 SuzukiH KirylukK NovakJ The pathophysiology of IgA nephropathy J Am Soc Nephrol 2011 22 1795 803 Search in Google Scholar

6. Saha MK, Julian BA, Novak J, Rizk DV. Secondary IgA nephropathy. Kidney Int. 2018 Oct;94(4):674–681 SahaMK JulianBA NovakJ RizkDV Secondary IgA nephropathy Kidney Int. 2018 Oct 94 4 674 681 Search in Google Scholar

7. Pitcher D, Braddon F, Hendry B et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol 2023; 18:727–38 PitcherD BraddonF HendryB Long-term outcomes in IgA nephropathy Clin J Am Soc Nephrol 2023 18 727 38 Search in Google Scholar

8. Moriyama T, Tanaka K, Iwasaki C et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single centre in Japan. PLoS One 2014;9:e91756. MoriyamaT TanakaK IwasakiC Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single centre in Japan PLoS One 2014 9 e91756 Search in Google Scholar

9. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S): S1–S276. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases Kidney Int. 2021 Oct 100 4S S1 S276 Search in Google Scholar

10. Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new international risk- prediction tool in IgA nephropathy. JAMA Intern Med. 2019; 179:942–952 BarbourSJ CoppoR ZhangH Evaluating a new international risk- prediction tool in IgA nephropathy JAMA Intern Med 2019 179 942 952 Search in Google Scholar

11. Rovin BH, Adler SG, Barratt J et al. Executive summary of the KDIGO 2021 Guideline for the management of glomerular diseases. Kidney Int 2021; 100:753–79 RovinBH AdlerSG BarrattJ Executive summary of the KDIGO 2021 Guideline for the management of glomerular diseases Kidney Int 2021 100 753 79 Search in Google Scholar

12. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016; 387:435–443 XieX AtkinsE LvJ Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis Lancet 2016 387 435 443 Search in Google Scholar

13. Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016; 67:728–741 XieX LiuY PerkovicV Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials Am J Kidney Dis 2016 67 728 741 Search in Google Scholar

14. Heerspink HJL, Stefansson BV, Correa-Rotter R et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–46 HeerspinkHJL StefanssonBV Correa-RotterR Dapagliflozin in patients with chronic kidney disease N Engl J Med 2020 383 1436 46 Search in Google Scholar

15. The E-KCG, Herrington WG, Staplin N et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388:117–27 The E-KCG HerringtonWG StaplinN Empagliflozin in patients with chronic kidney disease N Engl J Med 2023 388 117 27 Search in Google Scholar

16. Wheeler DC, Toto RD, Stefansson BV et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100:215–24 WheelerDC TotoRD StefanssonBV A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy Kidney Int 2021 100 215 24 Search in Google Scholar

17. EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant 2022; 37:1317–29 EMPA-KIDNEY Collaborative Group Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial Nephrol Dial Transplant 2022 37 1317 29 Search in Google Scholar

18. Natale P, Palmer SC, Ruospo M, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020;3:CD003965 NataleP PalmerSC RuospoM Immunosuppressive agents for treating IgA nephropathy Cochrane Database Syst Rev 2020 3 CD003965 Search in Google Scholar

19. Rauen T, Eitner F, Fitzner C et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–36 RauenT EitnerF FitznerC Intensive supportive care plus immunosuppression in IgA nephropathy N Engl J Med 2015 373 2225 36 Search in Google Scholar

20. Lv J, Wong MG, Hladunewich MA et al. Effect of oral methyl- prednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2022; 327:1888–98 LvJ WongMG HladunewichMA Effect of oral methyl- prednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial JAMA 2022 327 1888 98 Search in Google Scholar

21. Hou FF, Xie D, Wang J et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open 2023;6:e2254054 HouFF XieD WangJ Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial JAMA Netw Open 2023 6 e2254054 Search in Google Scholar

22. Stefan G, Mircescu G. Hydroxychloroquine in IgA nephropathy: a systematic review. Ren Fail 2021; 43:1520–7 StefanG MircescuG Hydroxychloroquine in IgA nephropathy: a systematic review Ren Fail 2021 43 1520 7 Search in Google Scholar

23. Duan J, Liu D, Duan G et al. Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta- analysis. Int Urol Nephrol 2017; 49:103–12 DuanJ LiuD DuanG Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta- analysis Int Urol Nephrol 2017 49 103 12 Search in Google Scholar

24. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383:2219–2229. BakrisGL AgarwalR AnkerSD Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes N Engl J Med 2020 383 2219 2229 Search in Google Scholar

25. Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 2023 HeerspinkHJL RadhakrishnanJ AlpersCE Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial Lancet 2023 Search in Google Scholar

26. Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 2022 BarrattJ LafayetteR KristensenJ Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy Kidney Int 2022 Search in Google Scholar

27. Kiryluk K. GWAS defines pathogenic signaling pathways and prioritizes 5 drug targets for IgA nephropathy. MedRxIV 2021. KirylukK GWAS defines pathogenic signaling pathways and prioritizes 5 drug targets for IgA nephropathy MedRxIV 2021 Search in Google Scholar

28. Zhai YL, Zhu L, Shi SF, et al. Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy. Medicine (Baltimore) 2016; 95:e3099 ZhaiYL ZhuL ShiSF Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy Medicine (Baltimore) 2016 95 e3099 Search in Google Scholar

29. Barratt J HB, Schwartz BS, Sorensen B, Roy SE, Stromatt CL, MacDonald M, Endlsey AN, Lo J, Glicklich A, King AJ: Pharmacodynamic and Clinical Responses to BION-1301 in Patients with IgA Nephropathy: Initial Results of a Ph1/2 Trial. In ASN Kidney Week 2021, 2021 BarrattJ HB SchwartzBS SorensenB RoySE StromattCL MacDonaldM EndlseyAN LoJ GlicklichA KingAJ Pharmacodynamic and Clinical Responses to BION-1301 in Patients with IgA Nephropathy: Initial Results of a Ph1/2 Trial In ASN Kidney Week 2021 2021 Search in Google Scholar

30. Mathur M, Barratt J, Suzuki Y, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep 2022; 7: 993–1003. MathurM BarrattJ SuzukiY Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers Kidney Int Rep 2022 7 993 1003 Search in Google Scholar

31. Cheung CK, Dormer JP, Barratt J. The role of complement in glomerulonephritis - are novel therapies ready for prime time? Nephrol Dial Transplant 2022 CheungCK DormerJP BarrattJ The role of complement in glomerulonephritis - are novel therapies ready for prime time? Nephrol Dial Transplant 2022 Search in Google Scholar

32. Bruchfeld A, Magin H, Nachman P, et al. C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study. Clin Kidney J 2022; 15: 922–928 BruchfeldA MaginH NachmanP C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study Clin Kidney J 2022 15 922 928 Search in Google Scholar

33. Lafayette RA, Rovin BH, Reich HN, et al. Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. Kidney Int Rep 2020; 5: 2032–2041 LafayetteRA RovinBH ReichHN Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy Kidney Int Rep 2020 5 2032 2041 Search in Google Scholar

34. Barratt J RB, Zhang H, Kashihara N, Maes B, Rizk D, Trimarchi H, Sprangers B, Meier M, Kollins D, Wang W, Magirr A, Perkovic V. POS-546 Efficacy and Safety of Iptacopan in IgA Nephropathy: Results of a Randomized Double-Blind Placebo-Controlled Phase 2 Study at 6 Months. Kidney International Reports 2022; 7. BarrattJ RB ZhangH KashiharaN MaesB RizkD TrimarchiH SprangersB MeierM KollinsD WangW MagirrA PerkovicV POS-546 Efficacy and Safety of Iptacopan in IgA Nephropathy: Results of a Randomized Double-Blind Placebo-Controlled Phase 2 Study at 6 Months Kidney International Reports 2022 7 Search in Google Scholar

35. Patrick J Gleeson, Michelle M O'Shaughnessy, Jonathan Barratt, IgA nephropathy in adults treatment standard, Nephrology Dialysis Transplantation, Volume 38, Issue 11, November 2023, Pages 2464–2473 GleesonPatrick J O'ShaughnessyMichelle M BarrattJonathan IgA nephropathy in adults treatment standard Nephrology Dialysis Transplantation 38 11 November 2023 2464 2473 Search in Google Scholar